Azad Engineering signs strategic supply agreement with Nuovo Pignone
By Aman Shukla Published on May 19, 2025, 20:48 IST
Azad Engineering has entered into an additional contract—Amendment No. 1—to the Strategic Supply Agreement (SSA) originally signed on March 6, 2024, with Nuovo Pignone Srl. Nuovo Pignone is a subsidiary of Baker Hughes Company, headquartered at Via F. Matteucci, 2, 50127 Firenze (FI), Italy.
The latest agreement extends the strategic collaboration for a period of five years and focuses on the supply of high-complexity and critical components. This marks a continued commitment between the two companies in delivering precision-engineered solutions for industrial applications.
The financial terms of the contract remain undisclosed. There is no shareholding involved between Azad Engineering and Nuovo Pignone, and the agreement does not fall under related party transactions. It is a long-term international contract and does not involve any issuance of shares or appointment of board nominees.
This extension reinforces Azad Engineering's position as a key supplier of specialized components to global industrial leaders like Baker Hughes, reflecting mutual confidence in quality, capability, and delivery standards.
Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at BusinessUpturn.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
3 hours ago
- Business Upturn
NHPC declares COD for 3rd phase of Karnisar Solar Power Project in Bikaner
NHPC Limited has announced the commencement of commercial operations for the third phase of its 300 MW Karnisar Solar Power Project in Bikaner, Rajasthan. Following the successful completion of the trial run on June 5, 2025, the company declared the Commercial Operation Date (COD) for the third phase—adding 53.57 MW of capacity—effective June 7, 2025. With this milestone, the total commercially operational capacity of the Karnisar Solar Power Project now stands at 160.71 MW out of the planned 300 MW. This phased commissioning highlights NHPC's continued commitment to expanding its renewable energy portfolio and supporting India's clean energy transition. The project is a part of NHPC's broader strategy to diversify its energy mix beyond hydropower and contribute significantly to the nation's solar capacity. It aligns with India's ambitious renewable energy goals and showcases NHPC's growing presence in the solar sector. NHPC Q4 Results NHPC has reported a strong 52% year-on-year (YoY) jump in its consolidated net profit to ₹919.63 crore for the fourth quarter ended March 2025, compared to ₹605 crore in the same quarter last year. According to the company's regulatory filing, the impressive performance was primarily driven by a rise in total income, which grew to ₹2,672.11 crore in Q4 FY25 from ₹2,320.18 crore in Q4 FY24. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
a day ago
- Business Upturn
Nazara Technologies acquires Smaaash Entertainment, invests Rs 126 crore
By Aditya Bhagchandani Published on June 7, 2025, 16:23 IST Nazara Technologies Limited has officially acquired Smaaash Entertainment Private Limited, marking a strategic expansion in the gaming and entertainment space. The development follows the approval of Nazara's resolution plan by the National Company Law Tribunal (NCLT), Mumbai Bench. As part of the deal, Nazara has infused Rs 10 crore in equity to acquire 100% of Smaaash's shareholding, making it a wholly owned subsidiary. Additionally, the company extended an unsecured inter-corporate loan of Rs 116 crore to Smaaash for settling creditor dues, bringing the total investment to Rs 126 crore. Smaaash, known for its immersive gaming and entertainment centres across India, reported revenue of Rs 112.34 crore in FY24. The acquisition, completed on June 6, 2025, aligns with Nazara's strategy of inorganic growth in the gaming sector. The company also stated that the acquisition was not a related party transaction and all required regulatory approvals were obtained. Nazara now has full control over Smaaash's operations, which include popular entertainment offerings such as bowling, go-karting, and other gaming formats across 11 locations in India. The move is expected to strengthen Nazara's presence in the experiential gaming domain. Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Upturn
a day ago
- Business Upturn
Lupin gets U.S. FDA tentative approval for Generic Oxcarbazepine ER Tablets
Lupin Limited has announced that it has received tentative approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Oxcarbazepine Extended-Release (ER) Tablets in 150 mg, 300 mg, and 600 mg strengths. These tablets are the generic equivalent of Oxtellar XR® ER Tablets by Supernus Pharmaceuticals and are indicated for the treatment of partial-onset seizures in patients aged 6 years and above. Lupin's version of the drug will be manufactured at its Nagpur facility in India. According to IQVIA MAT April 2025 data, Oxcarbazepine ER Tablets (RLD Oxtellar XR®) recorded estimated annual sales of USD 206 million in the United States, underscoring the potential market opportunity for Lupin. Headquartered in Mumbai, Lupin is a leading global pharmaceutical company with a strong footprint in the U.S. and India. The company focuses on a broad range of therapy areas including central nervous system disorders, respiratory, cardiovascular, anti-infective, and women's health. It operates 15 manufacturing sites and 7 research centers globally, supported by over 23,000 employees. Lupin continues to expand its U.S. portfolio of complex generics and remains committed to delivering high-quality, affordable medicines that improve health outcomes for patients around the world. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
